Medici List crest

RESMED INC

CIK: 9438192 Annual ReportsLatest: 2026-08-13
Revenue: $5,653,443,000Net Income: $1,523,293,000Source 10-K
Disclaimer: AI-assisted summary of SEC Form 10-K filings. Not official company content and not investment, legal, accounting, or tax advice. See full disclaimer here.

10-K / August 13, 2026

Revenue:$5,653,443,000
Income:$1,523,293,000

10-K / August 9, 2024

Revenue:$4,685,297,000
Income:$1,020,951,000

10-K / August 13, 2026

ResMed Inc. and Subsidiaries

Core business and leadership

  • Global leader in digital health and cloud-connected medical devices.
  • Focused on AI-powered digital health solutions, cloud-connected devices, and intelligent software.
  • Aims to make home healthcare more personalized, accessible, and effective.
  • Objectives include improving quality of life, reducing the impact of chronic disease, and lowering costs for consumers and healthcare systems.

History and primary product focus

  • Founded in 1989; pioneered continuous positive airway pressure (CPAP) therapy as the first successful non-invasive treatment for obstructive sleep apnea (OSA).
  • CPAP systems deliver pressurized air through a mask to prevent airway collapse during sleep.
  • Expanded product portfolio through internal development and acquisitions to address a broad range of sleep and related breathing health disorders.

Product areas include:

  • Technologies for medical and consumer products
  • Life support and ventilation devices
  • Diagnostic products
  • Hospital and home mask systems, headgear, and accessories
  • Dental devices

Cloud, software, and connected care

  • Strong emphasis on cloud-based health applications, software, and connected devices.
  • Solutions are designed to help clinicians manage more patients efficiently and to support patients’ long-term adherence and satisfaction with therapy.

Notable acquisitions and portfolio expansion

  • In June 2026, ResMed acquired Noctrix Health, LLC, a company with an FDA De Novo classified medical device for restless legs syndrome.
  • Noctrix will operate as a wholly owned subsidiary of ResMed.
  • The acquisition expands the clinical sleep health portfolio into an adjacent unmet need.
  • Further details are included in Note 18 – Business Combinations and Divestitures of the Notes to Consolidated Financial Statements.